CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy

Podobne zapisy

• CD19/CD22 Dual‐Targeted CAR‐T Therapy Active in Relapsed/Refractory DLBCL
  Wydane: (2020)
• Thapa B, Caimi PF, Ardeshna KM, et al. CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. Blood Adv. 2020;4(16):3850-3852.
  Wydane: (2020)
• CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
  od: Liang, Yun, i wsp.
  Wydane: (2021)
• Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL
  od: Tabbara, Nadeem, i wsp.
  Wydane: (2021)
• CAR therapy: the CD19 paradigm
  od: Sadelain, Michel
  Wydane: (2015)